title: Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
abstract: Plerixafor (P), an agent that selectively and reversibly binds to the chemokine receptor CXCR4, has been approved in combination with G-CSF (P + G-CSF) for stem cell (SC) mobilization in patients with multiple myeloma (MM). The goal of this study was to determine the SC collection success rate of P + G-CSF using a clinically relevant outcome defined as the ability to collect at least 5 × 106CD34+cells/kg to allow safely two transplants, and identify risk factors impacting SC mobilization. One hundred and thirty-eight patients were mobilized with P + G-CSF upfront following induction. The SC collection success rate was 92.8%. We identified exposure to lenalidomide alone (p = .038), WBC count <4 × 103/mcL prior to mobilization (p = .01) and non-African American race (p = .019), as risk factors for low efficiency by multivariate analysis. This study demonstrates that P + G-CSF is highly efficient in MM patients and provides strong support for its upfront use in SC collection for MM patients.
authors.affiliation: a Department of Pharmacy , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Adebayo
authors.initials: A
authors.lastname: Ogunniyi
authors.affiliation: a Department of Pharmacy , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Mabel
authors.initials: M
authors.lastname: Rodriguez
authors.affiliation: b Department of Epidemiology and Biostatistics , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Sean
authors.initials: S
authors.lastname: Devlin
authors.affiliation: a Department of Pharmacy , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Nelly
authors.initials: N
authors.lastname: Adel
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Landau
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Chung
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Nikoletta
authors.initials: N
authors.lastname: Lendvai
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Lesokhin
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Guenther
authors.initials: G
authors.lastname: Koehne
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Neha
authors.initials: N
authors.lastname: Korde
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Lilian
authors.initials: L
authors.lastname: Reich
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.affiliation: c Department of Medicine , Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York , NY , USA.
authors.forename: Hani
authors.initials: H
authors.lastname: Hassoun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001596:Benzylamines; D015415:Biomarkers; D000080027:Cyclams; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001596:Benzylamines; D015415:Biomarkers; D000080027:Cyclams; D006571:Heterocyclic Compounds; D007132:Immunoglobulin Isotypes; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor
keywords: Multiple myeloma; efficiency; mobilization; plerixafor; risk factors; stem cell